Sensei Biotherapeutics Inc
F:407
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sensei Biotherapeutics Inc
F:407
|
US |
|
O
|
Oma Saastopankki Oyj
OMXH:OMASP
|
FI |
|
Rheinmetall AG
XETRA:RHM
|
DE |
|
U
|
United States Antimony Corp
AMEX:UAMY
|
US |
|
S
|
Shenzhen Dobot Corp Ltd
HKEX:2432
|
CN |
|
A
|
Argo Group International Holdings Ltd
F:3AR
|
BM |
|
MNC Kapital Indonesia Tbk PT
IDX:BCAP
|
ID |
|
E
|
Erste Group Bank AG
XMUN:EBO
|
AT |
|
E
|
Engcon AB
STO:ENGCON B
|
SE |
|
Allos SA
BOVESPA:ALOS3
|
BR |
|
P
|
POWR Lithium Corp
CNSX:POWR
|
CA |
|
W
|
Welcron Co Ltd
KOSDAQ:065950
|
KR |
|
I
|
Ianthus Capital Holdings Inc
CNSX:IAN
|
CA |
|
J
|
JTF International Holdings Ltd
HKEX:8479
|
CN |
Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 56 full-time employees. The company went IPO on 2021-02-04. The firm is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The firm is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). The company also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The firm is also engaged in developing a monoclonal antibody (mAb) therapy.
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 56 full-time employees. The company went IPO on 2021-02-04. The firm is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The firm is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). The company also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The firm is also engaged in developing a monoclonal antibody (mAb) therapy.
